NasdaqGS:BNTXBiotechs
BioNTech (BNTX) Cuts 2026 Guidance On An Undervalued Story Or Fair Warning
BioNTech (NasdaqGS:BNTX) cut its 2026 revenue guidance to a range of €1,600 million to €1,900 million from €2,000 million to €2,300 million. The update followed second quarter results, which showed higher losses and lower sales.
See our latest analysis for BioNTech.
BioNTech's share price has moved to $93.67 after the guidance cut and wider earnings release, with a 7 day share price return of 3.41% and a year to date share price return that is down 3.12%. Over a longer window, momentum has...